{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:29:31Z","timestamp":1793212171233,"version":"4.5.0"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Phytomedicine"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.phymed.2019.152905","type":"journal-article","created":{"date-parts":[[2019,3,30]],"date-time":"2019-03-30T19:20:52Z","timestamp":1553973652000},"page":"152905","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":181,"special_numbering":"C","title":["Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review"],"prefix":"10.1016","volume":"60","author":[{"given":"Marie-Aleth","family":"Lacaille-Dubois","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phymed.2019.152905_bib0001","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1086\/656190","article-title":"Evaluation of the safety and immunogenicity of the RTS,S\/AS01E malaria candidate vaccine when integrated in the expanded program of immunization","volume":"202","author":"Agnandji","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.phymed.2019.152905_bib0002","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2217\/fmb.15.90","article-title":"Clinical development of RTS,S\/AS malaria vaccine, a systematic review of clinical phase I-III trials","volume":"10","author":"Agnandji","year":"2015","journal-title":"Future Microbiol."},{"key":"10.1016\/j.phymed.2019.152905_bib0003","doi-asserted-by":"crossref","first-page":"e18891","DOI":"10.1371\/journal.pone.0018891","article-title":"T cell responses to the RTS,S\/AS01E and RTS,S\/AS02D malaria candidate vaccines administered according to different schedules to Ghanaian children","volume":"6","author":"Ansong","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.phymed.2019.152905_bib0004","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2174\/1567205012666150302154121","article-title":"Vanutide cridificar and the QS-21 adjuvant in Japanese subjects with mild to moderate Alzheimer disease: results from two phase 2 studies","volume":"12","author":"Arai","year":"2015","journal-title":"Curr. Alzheimer Res."},{"issue":"114","key":"10.1016\/j.phymed.2019.152905_bib0005","first-page":"1","article-title":"Mechanisms of action of adjuvants","volume":"4","author":"Awate","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phymed.2019.152905_bib0006","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.bbamem.2014.12.005","article-title":"Detection of liposomal cholesterol and monophosphoryl lipid A by QS-21 saponin and Limulus polyphemus amebocyte lysate","volume":"1848","author":"Beck","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.phymed.2019.152905_bib0007","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.vaccine.2014.01.019","article-title":"Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit vaccine in older adults: a phase II, randomized controlled study","volume":"32","author":"Chlibek","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.phymed.2019.152905_bib0008","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.vaccine.2015.09.073","article-title":"Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults","volume":"34","author":"Chlibek","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.phymed.2019.152905_bib0009","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41541-017-0027-3","article-title":"Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFN\u03b3 response promoting vaccine immunogenicity","volume":"2","author":"Coccia","year":"2017","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.phymed.2019.152905_bib0010","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of Herpes\u2013Zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phymed.2019.152905_bib0011","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/infdis\/jiy095","article-title":"Immune responses to a recombinant glycoprotein E Herpes Zoster vaccine in adults aged 50 years or older","volume":"217","author":"Cunningham","year":"2018","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.phymed.2019.152905_bib0012","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.smim.2018.05.001","article-title":"Correlates of adjuvanticity: a review on adjuvants in licenced vaccines","volume":"39","author":"Del Giudice","year":"2018","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.phymed.2019.152905_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2012.01.088","article-title":"Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS-21 in mice","volume":"30","author":"Dendouga","year":"2012","journal-title":"Vaccine"},{"issue":"39475","key":"10.1016\/j.phymed.2019.152905_bib0014","first-page":"1","article-title":"Central role of CD169+ lymph node resident macrophages in the adjuvanticity of the QS-21 component of AS01","volume":"6","author":"Detienne","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phymed.2019.152905_bib0015","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.4049\/jimmunol.1400948","article-title":"Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells","volume":"193","author":"Didierlaurent","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.phymed.2019.152905_bib0016","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14760584.2016.1213632","article-title":"Adjuvant system AS01: helping to overcome the challenges of modern vaccines","volume":"16","author":"Didierlaurent","year":"2017","journal-title":"Expert Rev. Vaccines"},{"issue":"6","key":"10.1016\/j.phymed.2019.152905_bib0017","doi-asserted-by":"crossref","first-page":"e2673","DOI":"10.1097\/MD.0000000000002673","article-title":"The F4\/AS01B HIV-1 vaccine candidate is safe and immunogenic, but doesn't show viral efficacy in antiretroviral therapy-na\u00efve, HIV-1 infected adults: a randomized controlled trial","volume":"95","author":"Dinges","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.phymed.2019.152905_bib0077","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3390\/vaccines3020320","article-title":"Vaccine adjuvants: from 1920 to 2015 and beyond","volume":"3","author":"Di Pasquale","year":"2015","journal-title":"Vaccines"},{"key":"10.1016\/j.phymed.2019.152905_bib0018","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S1470-2045(18)30254-7","article-title":"MAGE-A3 immunotherapeutic as ajuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double blind, randomized, placebo-controlled, phase 3 trial","volume":"19","author":"Dreno","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phymed.2019.152905_bib0019","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1200\/JCO.2012.47.9303","article-title":"Adjuvant ganglioside GM2-KLH\/QS-21 vaccination versus observation after resection of primary tumor >1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial","volume":"31","author":"Eggermont","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phymed.2019.152905_bib0021","first-page":"683","article-title":"MAGE-A3: an immunogenic target used in clinical practice","volume":"7","author":"Esfandiary","year":"2015","journal-title":"Future Med."},{"key":"10.1016\/j.phymed.2019.152905_bib0022","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1515\/pac-2016-1213","article-title":"Design, synthesis and evaluation of optimized saponin variants derived from the vaccine adjuvant QS-21","volume":"89","author":"Fern\u00e1ndez-Tejada","year":"2017","journal-title":"Pure Appl. Chem."},{"key":"10.1016\/j.phymed.2019.152905_bib0023","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/nchem.1963","article-title":"Development of a minimal saponin vaccine adjuvant bsed on QS-21","volume":"6","author":"Fern\u00e1ndez-Tejada","year":"2014","journal-title":"Nat. Chem."},{"key":"10.1016\/j.phymed.2019.152905_bib0024","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1021\/acs.accounts.6b00242","article-title":"Development of improved vaccine adjuvants based on the saponin natural product QS-21 through chemical synthesis","volume":"49","author":"Fern\u00e1ndez-Tejada","year":"2016","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.phymed.2019.152905_bib0025","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/21645515.2016.1225635","article-title":"From discovery to licensure, the adjuvant system story","volume":"13","author":"Gar\u00e7on","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.phymed.2019.152905_bib0026","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1586\/14760584.6.5.723","article-title":"GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives","volume":"6","author":"Gar\u00e7on","year":"2007","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.phymed.2019.152905_bib0027","first-page":"89","article-title":"Vaccine adjuvants","volume":"1","author":"Gar\u00e7on","year":"2011","journal-title":"Understanding Modern Vaccines: Perspectives in Vaccinology"},{"key":"10.1016\/j.phymed.2019.152905_bib0028","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrmicro1681","article-title":"The perfect mix: recent progress in adjuvant research","volume":"5","author":"Guy","year":"2007","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.phymed.2019.152905_bib0029","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1016\/j.vaccine.2013.10.030","article-title":"Safetey and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomized placebo-controlled study","volume":"32","author":"Harrer","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.phymed.2019.152905_bib0030","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1016\/j.vaccine.2018.03.043","article-title":"Long-term follow-up of HIV-1-infected adults who received the F4\/AS01B HIV-1 vaccine candidate in two randomized controlled trials","volume":"36","author":"Harrer","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.phymed.2019.152905_bib0031","doi-asserted-by":"crossref","first-page":"696","DOI":"10.2174\/1567205014666170117101537","article-title":"Long term extensions of randomized vaccination trials of ACC-001 and QS-21 in mild to moderate Alzheimer's disease","volume":"14","author":"H\u00fcll","year":"2017","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.phymed.2019.152905_bib0032","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.tube.2014.07.001","article-title":"Safety and immunogenicity of the M72\/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: an open-label randomized controlled trial","volume":"94","author":"Ikodo","year":"2014","journal-title":"Tuberculosis"},{"key":"10.1016\/j.phymed.2019.152905_bib0033","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1073\/pnas.1621489114","article-title":"System analysis of protective immune responses to RTS,S malaria vaccination in humans","volume":"114","author":"Kazmin","year":"2017","journal-title":"PNAS"},{"key":"10.1016\/j.phymed.2019.152905_bib0034","first-page":"1","article-title":"Saponins as vaccine adjuvants","volume":"13","author":"Kensil","year":"1996","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.phymed.2019.152905_bib0035","doi-asserted-by":"crossref","first-page":"431","DOI":"10.4049\/jimmunol.146.2.431","article-title":"Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex","volume":"146","author":"Kensil","year":"1991","journal-title":"J. Immunol."},{"key":"10.1016\/j.phymed.2019.152905_bib0036","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1086\/600120","article-title":"Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S\/AS01B and RTS,S\/AS02A in malaria-na\u00efve adults: safety, efficacy, and immunologic associates of protection","volume":"2009","author":"Kester","year":"2009","journal-title":"J. Inf. Dis."},{"key":"10.1016\/j.phymed.2019.152905_bib0037","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0944-7113(96)80081-X","article-title":"A review of the biological and pharmacological activities of saponins","volume":"2","author":"Lacaille-Dubois","year":"1996","journal-title":"Phytomedicine"},{"key":"10.1016\/j.phymed.2019.152905_bib0038","first-page":"633","article-title":"Bioactive saponins from plants: an update","volume":"21","author":"Lacaille-Dubois","year":"2000"},{"key":"10.1016\/j.phymed.2019.152905_bib0039","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.phymed.2017.10.019","article-title":"New perspectives for natural triterpene glycosides as potential adjuvants","volume":"37","author":"Lacaille-Dubois","year":"2017","journal-title":"Phytomedicine"},{"key":"10.1016\/j.phymed.2019.152905_bib0040","series-title":"Immunomodulatory Agents from Plants","first-page":"243","article-title":"Saponins as immunoadjuvants and immunostimulants","author":"Lacaille-Dubois","year":"1999"},{"key":"10.1016\/j.phymed.2019.152905_bib0041","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1572-5995(05)80057-2","article-title":"Bioactive saponins with cancer related and immunomodulatory activity: recent developments","volume":"32","author":"Lacaille-Dubois","year":"2005","journal-title":"Stud. Nat. Prod. Chem."},{"key":"10.1016\/j.phymed.2019.152905_bib0042","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted Herpes Zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phymed.2019.152905_bib0043","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4110\/in.2015.15.2.51","article-title":"Recent advances of vaccine adjuvants for infectious diseases","volume":"15","author":"Lee","year":"2015","journal-title":"Immune Netw."},{"key":"10.1016\/j.phymed.2019.152905_bib0045","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.4161\/hv.29375","article-title":"Evaluation of the immune response to RTS,S\/AS01 and RTS,S\/AS02 adjuvanted vaccines","volume":"10","author":"Leroux-Roels","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.phymed.2019.152905_bib0044","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1128\/CVI.00617-13","article-title":"Immunogenicity and safety of a booster dose of an investigantional adjuvanted polyprotein HIV-1 vaccine in healthy adults and effect of administered chloroquine","volume":"21","author":"Leroux-Roels","year":"2014","journal-title":"Clin. Vacc. Immunol."},{"key":"10.1016\/j.phymed.2019.152905_bib0046","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/j.vaccine.2012.05.035","article-title":"Improved CD4+ T cell responses to Mycobacterium tuberculosis in PPD negative adults by M72\/AS01 as compared to the M72\/AS02 and Mtb72F\/AS02 tuberculosis candidate vaccine formulations: a randomized trial","volume":"31","author":"Leroux-Roels","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.phymed.2019.152905_bib0047","doi-asserted-by":"crossref","first-page":"7016","DOI":"10.1016\/j.vaccine.2010.08.035","article-title":"Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp 120, Nef and Tat antigens formulated in three adjuvant systems","volume":"28","author":"Leroux-Roels","year":"2010","journal-title":"Vacine"},{"key":"10.1016\/j.phymed.2019.152905_bib0048","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/infdis\/jis497","article-title":"A phase 1\/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein E subunit vaccine candidate in young and older adults","volume":"206","author":"Leroux-Roels","year":"2012","journal-title":"J. Inf. Dis."},{"key":"10.1016\/j.phymed.2019.152905_bib0049","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3390\/vaccines2020297","article-title":"Vaccine potentiation by combination adjuvants","volume":"2","author":"Levast","year":"2014","journal-title":"Vaccines"},{"key":"10.1016\/j.phymed.2019.152905_bib0050","doi-asserted-by":"crossref","first-page":"8803","DOI":"10.1039\/C4OB01652A","article-title":"Amphiphilic nature of saponins and their effects on artificial and biological membranes and potential consequences for red blood and cancer cells","volume":"12","author":"Lorent","year":"2014","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.phymed.2019.152905_bib0051","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1359-6446(03)02864-2","article-title":"Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity","volume":"8","author":"Marciani","year":"2003","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.phymed.2019.152905_bib0052","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.tips.2018.03.005","article-title":"Elucidating the mechanisms of action of saponin-derived adjuvants","volume":"39","author":"Marciani","year":"2018","journal-title":"Trends Pharm. Sci."},{"key":"10.1016\/j.phymed.2019.152905_bib0053","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1074\/jbc.M115.683011","article-title":"Identification of QS-21 as an inflammasome-activating molecular component of saponin adjuvants","volume":"291","author":"Marty-Roix","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phymed.2019.152905_bib0054","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/21645515.2017.1381809","article-title":"Characterization of T-cell immune responses in clinical trials of the candidate RTS,S malaria vaccine","volume":"14","author":"Moris","year":"2018","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.phymed.2019.152905_bib0055","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S1473-3099(10)70262-0","article-title":"Efficacy of RTS,S\/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomized controlled trial","volume":"11","author":"Olotu","year":"2011","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.phymed.2019.152905_bib0056","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3233\/JAD-150376","article-title":"Two phase 2 multiple ascending dose studies of vanutide cridificar (ACC-001) and QS-21 adjuvant in mild-to-moderate Alzheimer's disease","volume":"51","author":"Pasquier","year":"2016","journal-title":"J. Alzheimer Dis."},{"key":"10.1016\/j.phymed.2019.152905_bib0057","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.vaccine.2015.05.088","article-title":"Safety and immunogenicity of vaccine M72\/AS01E in adolescents in a TB endemic setting","volume":"33","author":"Penn-Nicholson","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.phymed.2019.152905_bib0058","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/nm.3409","article-title":"Key roles of adjuvants in modern vaccines","volume":"19","author":"Reed","year":"2013","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.phymed.2019.152905_bib0059","article-title":"Efficacy and safety of the RTS,S\/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites","volume":"11","year":"2014","journal-title":"PLoS Med."},{"key":"10.1016\/j.phymed.2019.152905_bib0060","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","article-title":"Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial","volume":"386","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.phymed.2019.152905_bib0061","series-title":"\u201cVaccines\u201d, Section 1, General aspects of Vaccination","first-page":"14","article-title":"Vaccine immunology","author":"Siegrist","year":"2013"},{"key":"10.1016\/j.phymed.2019.152905_bib0062","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.vaccine.2015.12.024","article-title":"A systematic review and meta-analysis on the safety of newly adjuvanted vaccines amound children","volume":"7","author":"Stassijns","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.phymed.2019.152905_bib0063","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1080\/21645515.2018.1442162","article-title":"Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults","volume":"14","author":"Schwarz","year":"2018","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.phymed.2019.152905_bib0064","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/cid\/ciq160","article-title":"An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers","volume":"52","author":"Van Braeckel","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.phymed.2019.152905_bib0065","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3389\/fimmu.2017.00557","article-title":"Predicting RTS,S vaccine-mediated protection from transcriptomes in a malaria-challenge clinical trial","volume":"8","author":"Van den Berg","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phymed.2019.152905_bib0066","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1803484","article-title":"Phase 2b controlled trial of M72\/AS01E vaccine to prevent tuberculosis","volume":"379","author":"Van der Meeren","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phymed.2019.152905_bib0067","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.vaccine.2007.12.038","article-title":"Vaccine adjuvant systems containing monophosphoryl lipid A and QS-21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volonteers","volume":"26","author":"Vandepapeli\u00e8re","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.phymed.2019.152905_bib0068","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S1470-2045(16)00099-1","article-title":"Efficacy of the MAGE-A3 immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"Vansteenkiste","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phymed.2019.152905_bib0069","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1039\/C5SC02978C","article-title":"Quillaja saponin variants with central glycosidic linkage modifications exhibit distinct conformations and adjuvant activities","volume":"7","author":"Walkowicz","year":"2016","journal-title":"Chem. Sci."},{"key":"10.1016\/j.phymed.2019.152905_bib0070","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3389\/fimmu.2016.00663","article-title":"Lysosome-dependent activation of human dendritic cells by the vaccine adjuvant QS-21","volume":"7","author":"Welsby","year":"2017","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.phymed.2019.152905_bib0071","doi-asserted-by":"crossref","first-page":"e61395","DOI":"10.1371\/journal.pone.0061395","article-title":"The relationship between RTS,S vaccine-induced antibodies, CD4+ T cell responses and protection against Plasmodium falciparum infection","volume":"8","author":"White","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.phymed.2019.152905_bib0076","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/alzrt237","article-title":"Active immunotherapy options for Alzheimer's disease","volume":"6","author":"Winblad","year":"2014","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.phymed.2019.152905_bib0072","first-page":"33","article-title":"Malaria vaccine: WHO position paper-January 2016","volume":"91","year":"2016","journal-title":"Weekly Epidemiol. Rec."},{"key":"10.1016\/j.phymed.2019.152905_bib0075","unstructured":"www.ema.europa.eu\/en\/documents\/overview\/Shingrix-epar-medicine-overview_en.pdf. Shingrix, INN-herpes zoster vaccine (recombinant, adjuvanted). EMA\/76073\/2018."},{"key":"10.1016\/j.phymed.2019.152905_bib0078","unstructured":"www.ema.europa.eu\/en\/documents\/press-release\/first-malaria-vaccine-receives-positive-scientific-opinion-ema_en.pdf. EMA press release 2015. First malaria vaccine receives positive scientific opinion from EMA, 2015. EMA\/CHMP488348\/2015."},{"key":"10.1016\/j.phymed.2019.152905_bib0079","unstructured":"www.who.int\/campaigns\/malaria-day\/2018\/en\/. World Malaria Day, 25 April 2018."},{"key":"10.1016\/j.phymed.2019.152905_bib0073","unstructured":"www.who.int\/malaria\/media\/malaria-vaccine-implementation-qa\/en\/. WHO\/Q & A on the malaria vaccine implementation programme (MVIP) January 2019."},{"key":"10.1016\/j.phymed.2019.152905_bib0074","unstructured":"www.who.int\/news-room\/fact-sheets\/detail\/hiv-aids. HIV\/AIDS, Key facts, 19 July 2018."}],"container-title":["Phytomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0944711319300753?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0944711319300753?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T18:17:32Z","timestamp":1760552252000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0944711319300753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":78,"alternative-id":["S0944711319300753"],"URL":"https:\/\/doi.org\/10.1016\/j.phymed.2019.152905","relation":{},"ISSN":["0944-7113"],"issn-type":[{"value":"0944-7113","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review","name":"articletitle","label":"Article Title"},{"value":"Phytomedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phymed.2019.152905","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"152905"}}